Chemokine mutants in the treatment of multiple sclerosis

Details Chemokine mutants in the treatment of multiple sclerosis Chemokine mutants in the treatment of multiple sclerosis

A - Human Necessities

61

K

A61K 38/19 (2006.01) A61P 25/00 (2006.01) C07K 14/52 (2006.01) C12N 15/19 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2423616

Mutants of CC chemokines, which contain at least two mutations in the cationic site of the 40's loop and which, relative to the wild-type molecule, have a reduced GAG-binding activity. In particular it has been found that such mutated chemokines are effective in the treatment of multiple sclerosis and/or other demyelinating diseases. A triple mutant of RANTES is the compound showing the best results.

L'invention concerne des mutants de chimiokines CC, qui comportent au moins deux mutations dans le site cationique de la boucle 40's, et qui, par rapport à la molécule de type sauvage, présentent une activité réduite de liaison des glycosaminoglycans (GAG). En particulier, il apparaît que ces mutants sont efficaces dans le traitement de la sclérose en plaques et/ou d'autres troubles de démyélinisation. Un triple mutant de RANTES est le composé qui permet d'obtenir les meilleurs résultats.

Affiliated with

Also associated with

Rating

Chemokine mutants in the treatment of multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chemokine mutants in the treatment of multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemokine mutants in the treatment of multiple sclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1752760